Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab
Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab
复制标题
DOI：
10.3892/or_00000017
复制
发表时间：
2008-08-01
期刊：
影响因子：
4.2
通讯作者：
Tsukuda, Mamoru
中科院分区：
文献类型：
--
作者：
Kondo, Norio;Ishiguro, Yukari;Tsukuda, Mamoru
EGFR和/或HER-2的过表达与多种恶性肿瘤患者的肿瘤细胞对化疗、放疗的耐药性、疾病进展和预后不良有关。据报道，EGFR靶向药物吉非替尼（ZD 1839，易瑞沙）与HER-2靶向药物曲妥珠单抗（赫赛汀）联合治疗可提高乳腺癌患者的疗效。本研究的目的是检查这种组合在体外对头颈部鳞状细胞癌（HNSCC）的抗肿瘤作用。两种细胞系的细胞增殖均受到明显抑制。虽然吉非替尼单独对某些细胞系的IC 50未达到，但与曲妥珠单抗联合后达到。此外，在几种细胞系中，联合用药的IC 50低于吉非替尼单药。这些结果表明，该组合可以改善针对HNSCC的功效。
The overexpression of EGFR and/or HER-2 is associated with tumor cell resistance to chemotherapy, radiotherapy, disease progression and poor prognosis in patients with a variety of malignant tumors. Treatment combining the EGFR-targeting drug, gefitinib (ZD 1839, Iressa) with the HER-2-targeting drug, trastuzumab (Herceptin) has been reported to improve therapeutic efficacy in patients with breast cancer. The purpose of this study was to examine the antitumor effect of this combination on head and neck squamous cell carcinoma (HNSCC) in vitro. Cell proliferation was inhibited significantly in two cell lines. Although IC50 of gefitinib alone against some cell lines was not reached, it was achieved after being combined with trastuzumab. Furthermore, IC50 was lower for the combination than for gefitinib alone in several cell lines. These results suggest that the combination may improve efficacy against HNSCC.